Antibodies targeting cgpr and uses thereof

CN122325599APending Publication Date: 2026-07-03HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC
Filing Date
2025-11-06
Publication Date
2026-07-03

Smart Images

  • Figure CN122325599A_ABST
    Figure CN122325599A_ABST
Patent Text Reader

Abstract

This invention discloses an antibody targeting CGRP and its applications. The antibody or its antigen-binding portion comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2, and CDR-L3. This antibody can specifically bind to human and rat CGRP peptides and α / β subtype CGRP peptides with high affinity, blocking the binding of CGRP to its receptor CGRPR, reducing pain perception, and achieving the treatment of pain disorders such as migraines caused by CGRP. Furthermore, it can also relieve or treat hot flashes.
Need to check novelty before this filing date? Find Prior Art